Compare LCUT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCUT | ALXO |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 79.7M |
| IPO Year | 1991 | 2020 |
| Metric | LCUT | ALXO |
|---|---|---|
| Price | $4.05 | $1.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $5.00 | $3.30 |
| AVG Volume (30 Days) | 36.5K | ★ 340.5K |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | ★ 4.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $659,066,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.89 | $0.40 |
| 52 Week High | $7.05 | $2.27 |
| Indicator | LCUT | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 67.32 | 45.70 |
| Support Level | $3.49 | $1.29 |
| Resistance Level | $3.97 | $1.56 |
| Average True Range (ATR) | 0.20 | 0.16 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 92.78 | 29.45 |
Lifetime Brands Inc is a U.S. based company that designs, sources, and sells branded kitchenware, tableware, and other products used in the home and markets its products under brands such as Farberware, KitchenAid, Mikasa, and others. The company markets and sells its products principally on a wholesale basis to retailers. It also markets and sells a limited selection of its products directly to consumers through its Pfaltzgraff, Mikasa, Fred, and Friends, Built NY, and others. Its products include kitchen tools, gadgets, cutlery, dinnerware, and glassware. The segments of the company are the U.S. and International. It derives a majority of its revenue from the U.S. segment. The company derives maximum revenue from Kitchenware products.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.